SCHEMBL314646

SCHEMBL314646

COc1ccc2c[c]ccc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.54
CYP1A2 P05177 2/20 0.54
HSD17B1 P14061 1/20 0.47
HSD17B2 P37059 1/20 0.47
NQO1 P15559 1/20 0.44
KDM4E B2RXH2 1/20 0.44
GSTP1 P09211 1/20 0.44
NCF1 P14598 1/20 0.43
RAB9A P51151 2/20 0.42
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41
AKR1C3 P42330 4/20 0.41
AKR1C2 P52895 4/20 0.41
PTGS1 P23219 2/20 0.41
NPC1 O15118 1/20 0.41
CASP3 P42574 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
ABCB11 O95342 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL645546 0.94 CYP2A6 (0.57) CYP2A6CYP1A2HSD17B1HSD17B2NQO1
SCHEMBL2252619 0.92 CYP2A6 (0.50) CYP2A6CYP1A2HSD17B1HSD17B2NQO1
SCHEMBL2254126 0.92 CYP2A6 (0.50) CYP2A6CYP1A2HSD17B1HSD17B2NQO1
SCHEMBL1121819 0.80 NQO1 (0.48) CYP1A2NQO1KDM4EMEN1MAPK1
SCHEMBL6611816 0.80 AGXT (0.34) CYP2A6CYP1A2KDM4EGSTP1RAB9A
SCHEMBL208820 0.79 CYP1A2 (0.30) CYP2A6CYP1A2
SCHEMBL443070 0.79 CYP1A2 (0.79) CYP2A6CYP1A2HSD17B1HSD17B2NQO1
SCHEMBL29447161 0.79 CYP1A2 (0.79) CYP2A6CYP1A2HSD17B1HSD17B2NQO1
SCHEMBL7197554 0.79 CA12 (0.33) CYP2A6CYP1A2NQO1
SCHEMBL3142737 0.79 ALDH1A1 (0.41) KDM4EPOLBKMT2AAKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1693 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118184703-A Synthesis method of alpha-substituted chiral phosphonate compound 中国人民解放军军事科学院防化研究院 2024-06-14 CN claimed
US-11987588-B2 Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto ARENA PHARMACEUTICALS, INC. (US) 2024-05-21 US claimed
CN-117486907-A N 2 O-type BODIPY derivative and preparation method and application thereof 安徽师范大学 2024-02-02 CN claimed
CN-117430511-A Preparation and application of novel cinnamic acid analogue 广东轻工职业技术学院 2024-01-23 CN claimed
CN-117143340-A Preparation method and application of enol-terminated sulfhydryl compound 益丰新材料股份有限公司 2023-12-01 CN claimed
WO-2023169615-A1 DIAMINE COMPOUND WITH FLUORESCENT PROPERTIES, METHOD OF ITS PREPARATION, A POLYIMIDE FILM AND A POLYEPOXIDE CONTAINING THIS DIAMINE TOSEDA S.R.O. (CZ) 2023-09-14 WO claimed
CN-116621922-A PROTAC compound for degrading cyclooxygenase 2 and influenza virus nucleoprotein, and preparation method and application thereof 中国科学院微生物研究所 2023-08-22 CN claimed
WO-2023107547-A2 AZETIDINE AND SPIROAZETIDINE COMPOUNDS AND USES THEREOF Kineta, Inc. (US) 2023-06-15 WO claimed
EP-3720858-B1 MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO ARENA PHARM INC (US) 2023-06-07 EP claimed
CN-116199616-A Modified oxime ester compound, preparation method thereof and photo-curing composition 常州强力电子新材料股份有限公司 2023-06-02 CN claimed
US-4055651-A THROMBOSIS INHIBITORS MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) 1977-10-25 US claimed
US-4055636-A THROMBOSIS INHIBITORS MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) 1977-10-25 US claimed
US-4046876-A THROMBIN INHIBITORS MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) 1977-09-06 US claimed
US-4041156-A ANTITHROMBOGENIC AGENTS MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) 1977-08-09 US claimed
US-4036955-A TREATMENT OF THROMBOSIS MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) 1977-07-19 US claimed
US-4018915-A ANTITHROMBOTIC MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) 1977-04-19 US claimed
US-4018913-A N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) 1977-04-19 US claimed
US-4016196-A HEATING GLYCIDIC ESTERS NISSHIN FLOUR MILLING CO., LTD. (JA) 1977-04-05 US claimed
US-3993645-A Stilbene optical brighteners and compositions brightened therewith STERLING DRUG INC. (US) 1976-11-23 US claimed
US-3932301-A NYLON, POLYESTERS STERLING DRUG INC. (US) 1976-01-13 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11987588-B2 Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto ADRB3, ADRB1, ADRB2 CYP2A6 756/4885CYP1A2 633/4885HSD17B1 247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.